HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 —— ...

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

NDA supported by results from a Phase II registration trial in China —— Second most common form of liver cancer after hepatocellular carcinoma, ...
Pharmabiz

China NMPA accepts and grants priority review status to Hutchmed’s NDA for fanregratinib in second-line intrahepatic cholangiocarcinoma

China NMPA accepts and grants priority review status to Hutchmed’s NDA for fanregratinib in second-line intrahepatic cholangiocarcinoma: Hong Kong, Shanghai Wednesday, December ...
India TV

Wockhardt Share Price: Pharma stock surges over 6% as USFDA accepts NDA for antibiotic Zaynich

Shares of drug firm Wockhardt are in action even as the benchmark indices declined in early trade on Tuesday, December 2, 2025, amid uncertainty over repo rate cuts. The counter opened in green at Rs ...
Seeking Alpha

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HCM) (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the New Drug Application ( ...
Seeking Alpha

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

— NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — The NMPA granted ...